Mereo grants Sentynl US option for alvelestat in deal worth up to $475 million
- nuaxia
- 2 giorni fa
- Tempo di lettura: 3 min
The agreement gives Sentynl an exclusive pathway to commercialise the Phase III-ready rare lung disease therapy in the US while providing global manufacturing rights and funding support for late-stage development.
Mereo BioPharma has entered into an option and licence agreement with Sentynl Therapeutics for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), under which Mereo will receive a non-refundable option fee and, if the option is exercised, up to $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestones, plus tiered royalties on US sales.
The agreement allows Mereo to retain commercial rights outside the United States while partnering with Sentynl to prepare the Phase III programme for a therapy that could become the first oral treatment for AATD-LD.
Field | Content |
Alert Type | Deal |
Companies | Mereo BioPharma Group plc; Sentynl Therapeutics (Zydus Lifesciences) |
Deal Type | Option and licence agreement |
Asset or Company | Alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD) |
Therapy Area(s) | Rare respiratory diseases; Pulmonology |
Technology or Modality | Oral small-molecule neutrophil elastase inhibitor |
Deal Value | Non-refundable option fee (undisclosed); if exercised, up to $40 million in upfront and R&D payments, up to $435 million in regulatory and commercial milestone payments, plus double-digit tiered royalties on US net sales. Maximum disclosed potential value: up to $475 million, excluding royalties. |
Development Stage | Phase III-ready |
Geography | United States (commercial rights); Global manufacturing; Mereo retains commercial rights outside the US |
What Happened | On 11 August 2026, Mereo BioPharma and Sentynl Therapeutics announced an option and licence agreement covering US commercial rights and global manufacturing rights for alvelestat in AATD-LD. Mereo will continue to lead global Phase III development and regulatory interactions until completion of the study, while the companies collaborate during the option period to refine the Phase III design and manufacturing strategy. The agreement remains contingent on Sentynl exercising its commercialisation option. |
Why It Matters | The transaction provides Mereo with a development and commercial partner for the US market while allowing it to retain ex-US commercial rights. For Sentynl, the agreement expands its rare disease portfolio with a Phase III-ready programme targeting a rare genetic lung disease that currently has no approved oral treatment. |
Supporting Context | Alvelestat is an oral neutrophil elastase inhibitor being developed for AATD-LD and has demonstrated positive Phase II efficacy in two studies. It has received FDA Fast Track designation and Orphan Drug Designation in both the US and EU. If approved, it could become the first oral therapy specifically indicated for AATD-LD. |
Strategic Rationale | Mereo secures non-dilutive funding for late-stage development while retaining long-term commercial rights outside the US. Sentynl gains a late-stage rare disease asset that complements its existing portfolio and provides an opportunity to build its respiratory rare disease franchise. |
Potential Impact | If the option is exercised and Phase III development is successful, the partnership could accelerate the introduction of a targeted oral therapy for AATD-LD while expanding Sentynl's presence in rare respiratory diseases. Clinical success and regulatory approval remain dependent on future trial outcomes. |
Key Takeaway | The agreement combines late-stage development funding with a territory-specific commercial partnership, allowing Mereo to retain ex-US rights while positioning Sentynl to expand its rare disease portfolio in the United States. |
What to Watch | Exercise of Sentynl's commercialisation option, refinement of the Phase III study design, initiation of the global Phase III programme in early 2027, and subsequent regulatory milestones. |
Primary Source | |
Relevant Date | 11 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti